Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
American Journal of Surgery|August 7, 2022
Primary hyperparathyroidism after radioactive iodine therapy: Is it a distinct clinical entity?Iuliana Bobanga, Judy Jin, Scott Wilhelm, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Cancer Research|December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Li Liu, Yichen Cao, Charles Chen, et al.
Surgery|November 16, 2023
Early observations with an ERAS pathway for thyroid and parathyroid surgery: Moving the goalposts forwardNikita Machado, Ryland Mortlock, Richard Maduka, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancerScott Wilhelm, Christopher Carter, Mark Lynch, et al.
Cancer Medicine|October 14, 2016
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical modelsDieter Zopf, Iduna Fichtner, Ajay Bhargava, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
JAMA Surgery|August 17, 2022
American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive SummaryLinwah Yip, Quan-Yang Duh, Heather Wachtel, et al.
Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancerPhilip Wickens, Harold Kluender, Julie Dixon, et al.
Pageof 2